Show results for
Refine by
Schizophrenia Theraphy For Treatment Suppliers & Manufacturers
2 companies found
based inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
Schizophrenia is a chronic disease that manifests through disturbances of perception, thought, cognition, emotion, motivation and motor activity. Over a lifetime, about 1% of the population will develop ...
based inRye Brook, NEW YORK (USA)
Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Our pipeline includes our lead drug candidate, CM-AT, which is in a Phase III clinical trial for Autism, and is ...
More than 1% of the US adult population is affected by schizophrenia, with symptoms falling into three categories: positive (hallucinations and delusions), negative (flat affect, difficulty in social interactions) and cognitive (complications with ...